Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that focuses on developing orally bioavailable small molecule drugs to address a range of diseases. The company's primary aim is to target diseases where significant unmet medical needs exist, particularly in areas such as inflammation, cancer, and liver disease. Can-Fite leverages its proprietary platform which targets A3 adenosine receptor (A3AR), a key therapeutic target implicated in these conditions. By developing drugs that modulate this receptor, the company seeks to provide innovative treatments for conditions like rheumatoid arthritis and psoriasis. With a strong foundation in clinical development, Can-Fite BioPharma operates at the intersection of pharmaceutical innovation and disease management, contributing to advancements within the biotechnology sector. Headquartered in Petach Tikva, Israel, the company plays a crucial role in expanding the therapeutic horizons for chronic and severe health conditions, thus holding significant potential impact within both domestic and global health markets.